CRISPR Therapeutics reports up to 86% LDL reduction with CTX310; delays CTX320 data to H1 2026

CRISPR Therapeutics AG

CTX310 Phase 1 shows up to 82% TG and 86% LDL reductions at 0.8 mg/kg with stable liver enzymes.
CTX320 (LPA gene) Phase 1 data update expected in first half of 2026 due to strategic pause for Lp(a) landscape insights.
CTX340 (AGT gene) for refractory hypertension advancing through IND/CTA-enabling studies.
CTX310 trial enrolling HoFH, severe hypertriglyceridemia, HeFH, and mixed dyslipidemia patients.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.